ArticleHealth science reports2025
Chronic Respiratory Disease Prevalence, Burden, and Treatment in Cape Town: A Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: There is a high burden of respiratory symptoms in South Africa, but accurate classification of diagnoses is challenging. Due to the adverse risk profile, inhaled corticosteroid (ICS) treatment should only be used in specific conditions, such as asthma or chronic obstructive pulmonary disease (COPD) with eosinophilia. Those with tuberculosis or who are HIV-positive may be at particular risk. Hence, establishing underlying diagnoses and indications for ICS treatment is crucial. The primary aim was to establish the underlying diagnosis after investigations, the secondary aim was to identify any indication for ICS treatment (asthma or eosinophilia). Methods: We conducted a cross-sectional study of adults attending two hospitals in Cape Town, South Africa, with exacerbations of chronic respiratory diseases. Participants performed investigations at least 8 weeks after recruitment. Questionnaires and extensive investigations (full lung function with bronchodilator reversibility, allergy tests, computed tomography) were completed. Results: Between 2021 and 2023, a total of 224 participants were recruited, of whom 101 attended investigations, yet 40 died before they could attend. Most were current (49) or ex-smokers (40). A total of 46 previously had pulmonary tuberculosis. Post-tuberculosis lung disease (PTLD) with COPD (28) or COPD alone (27) were the most common diagnoses. Ten participants had asthma. Serum eosinophilia was present in 19 participants. There was no clear indication for ICS treatment for 5/7 participants who used ICS, and 22/30 who used ICS-long-acting beta-agonists combination. Conclusion: COPD and PTLD were more common, asthma and eosinophilia were less prevalent than expected. There was a high symptom burden. Modifiable risks (tuberculosis, smoking) were also common. ICS treatment appeared to be independent of underlying diagnosis and could lead to harm. Approximately 1 in 5 died shortly after admission. Strategies to better serve this patient group are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.